Inovio Pharmaceuticals discusses financial results and developments

Inovio Pharmaceuticals held its fourth quarter earnings call for 2024 on March 18, 2025. The call included key executives, such as the President and CEO, Dr. Jacqui Shea, and the Chief Financial Officer, Peter Kies. During the call, the team reviewed the company’s financial results for the quarter and the whole year, which ended on December 31, 2024. They also shared updates on ongoing projects and corporate activities. Jennie Willson from Investor Relations introduced the speakers and outlined the agenda. She mentioned that the call would include forward-looking statements about the company's plans. These plans involve developing Inovio's DNA medicines platform and include details on clinical trials, regulatory steps, and financial resources. The executives emphasized that their statements reflect management's outlook and are subject to change based on actual future events. A question-and-answer session followed their prepared remarks, allowing analysts to inquire further about the company's direction and performance.